2023
DOI: 10.21037/cdt-22-570
|View full text |Cite
|
Sign up to set email alerts
|

Management of concomitant central venous disease

Abstract: Symptomatic central venous disease (CVD) is a significant common problem in patients with end-stage renal disease given its adverse impact on hemodialysis (HD) vascular access (VA). The current mainstay management is percutaneous transluminal angioplasty (PTA) with or without stenting which is typically reserved for unsatisfactory angioplasty or more challenging lesions. Despite factors such as target vein diameters and lengths and vessel tortuosity that may determine the choice of bare-metal versus covered st… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 40 publications
0
1
0
Order By: Relevance
“…Two articles in this series address the challenge of central venous stenotic and occlusive disease in patients with chronic kidney disease. First, a paper by Alnahhal, Rowse, and Kirksey ( 15 ) provides an overview of management options for central venous disease. Second, an article by Rashwan and colleagues ( 16 ) describes endovascular recanalization techniques for central venous occlusion.…”
mentioning
confidence: 99%
“…Two articles in this series address the challenge of central venous stenotic and occlusive disease in patients with chronic kidney disease. First, a paper by Alnahhal, Rowse, and Kirksey ( 15 ) provides an overview of management options for central venous disease. Second, an article by Rashwan and colleagues ( 16 ) describes endovascular recanalization techniques for central venous occlusion.…”
mentioning
confidence: 99%